TRPA1 in Chemotherapy-Induced Peripheral Neuropathy: A Promising Target for Immunomodulation and Anti-Inflammatory Therapy

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and serious clinical condition that results when a chemotherapeutic agent damages the peripheral nervous system and is usually characterized by abnormal pain in the distal limbs and increased sensitivity to hot and cold stimuli. However, few clinical treatments for CIPN are available, so it is critical to identify effective treatment modalities. Transient receptor potential ankyrin 1 (TRPA1), an injury receptor, can be activated by oxidative stress, inflammatory mediators, and hypothermic conditions during the pathogenesis and progression of CIPN. TRPA1 modulates the downstream inflammatory pathway and promotes the release of inflammatory factors and neuropeptides, resulting in abnormal immune regulation, which in turn leads to a neurogenic inflammatory response and pain signaling. In this study, the role of TRPA1 in the pathogenesis of CIPN is examined, the possibility of targeting TRPA1 to treat CIPN by inhibiting neuroinflammation is verified, and the prospects of using TRPA1 antagonists and natural herbs for the clinical treatment of CIPN are explored.